Dr. Vincent de Luise MD
Assistant Clinical Professor of Ophthalmology , YALE UNIVERSITY
Member of the Healthcare Council
Council Member Biography
Vincent de Luise, MD, FACS, is an Assistant Clinical Professor of Ophthalmology at Yale University and the University of Connecticut Health Center. He is the Head of Cornea Service at OptiCare Eye Health Center, Waterbury CT, where he also has his private practice. Dr. de Luise is Education Chair of the Connecticut Society of Eye Physicians. He is an Ophthalmologist and Ophthalmic Surgeon specializing in cataract, astigmatism surgery intraocular lens (IOL) implant surgery, Toric (astigmatism) IOLs, Multifocal IOLs, accommodating IOLs, presbyopic IOLs, ReStor IOLs, LASIK surgery, refractive surgery, PRK, advanced surface ablation, DSEK and cornea transplantation. Dr. De Luise’s clinical research interests include dry eye disease, antibiotics for the eye, ophthalmic antibiosis, dry eye after LASIK, ocular infectious disease, herpes zoster ophthalmicus, and corneal transplantation. He has consulted for Otsuka, Senji Pharmaceuticals and is on the speakers' bureaus for Alcon, Allergan, Bausch & Lomb, and Merck. (This is me - Update Profile)
Employment History
- 2006 - Unspecified
- Assistant Clinical Professor of Ophthalmology , YALE UNIVERSITY
- 1984 - Unspecified
- Assistant Clinical Professor of Ophthalmology, University of Connecticut Health Center - CC
- 1982 - Unspecified
- Head of Cornea Service, OPTICARE EYE HEALTH CENTER P.C.
- 1982 - Unspecified
- Ophthalmologist, Vincent de Luise, MD, FACS
GLG NewsSM Analyses by Vincent de Luise(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Technical analysis of multifocal lens implants (IOLs) and astigmatism lens implants (Toric IOLs)
July 14, 2009
FDA Approves Alcon's AcrySof® IQ ReSTOR® +3.0 D Intraocular Lens - New Lens Corrects For Cataracts With Presbyopia | www.medicalnewstoday.com
There is a sea-change in cataract/lens implant (IOL) surgery. More than ever before, patients with cataracts want to able to see well without the need for glasses or contact lenses. Standard IOLs give very good vision, but many patients have pre-existing astigmatism and need correction for that with a Toric IOL, and those who want to see well for distance and near will require either a multifocal IOL (Alcon ReStor, AMO ReZoom or Technis ZM900 IOL) or an accommodative IOL (Bausch and Lomb Crystalens). Alcon's two IOLs, their Acrysof Toric IOL for astigmatism, and their newest multifocal IOL, the Alcon ReStor +3.0 D are showing good usage With respect to astigmatism, the two existing IOLs are the Staar Toric IOL and the Alcon Toric IOL, both of which work well. The multifocal Aspheric Alcon ReStor + 3.00 D is showing strong penetration because the + 3.00 D add allows for intermediate (computer vision) as well as near vision and less haloes and glare .
-
eye drop corticosteroids (topical steroids) for LASIK and cataract surgery and dry eye
June 23, 2009
steroids in eye surgery | www.siriontherapeutics.com
There are several potent cortisteroids (steroids) in the form of eye drops, which ophthalmologists use daily to manage postoperative healing after LASIK surgery cataract surgery, and intraolcular lens implant surgery. In addition, some steroid drops can be used for short intervals of time in managaing dry eye disease. These include pred forte (Allergan), omnipred (Alcon), Maxidex (Alcon), Lotemax (Bausch and Lomb) and Durezol (Sirion). These steroid drops have slghtly different biochemical structures and side effect profiles. In general,the more potent the steroid, the more likely it has a side effect of intraocular pressure rise (glaucoma risk) and cataract formation. Durezol, a newer topical steroid from Sirion Therapeutics, has excellent potency and slightly less of a side effects. Lotemax (Bausch and Lomb) has found a niche in the management of dry eye disease, being used for short intervals (a few weeks) in dry eye management, as other drops such as restasis get on board.
-
Pfizer Cut Issues and Observations
November 30, 2006
Pfizer to Cut Its U.S. Sales Force by 20% | www.nytimes.com
What is the effect of downsizing sales representatives on drug sales for Pfizer?
Leading institutions connect with Vincent de Luise through GLG
GLG Study Groups with Vincent de Luise(?)
GLG Live Meetings with Vincent de Luise(?)
Vincent de Luise has not participated in any GLG Live Meetings.